KRAS and neoplasm: In the 43 cases with available baseline tumor and blood samples (Fig. 2), high KRAS mutation abundances in both tumor (OS, P = 0.016; PFS, P = 0.046) and blood samples (OS, P < 0.001; PFS, P < 0.001) were significantly associated with poorer survival.